Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors [1][5][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1]. - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts [5][6]. - It is alleged that the Phase III studies were less likely to demonstrate the claimed efficacy than management suggested, resulting in investors purchasing shares at artificially inflated prices [6]. Group 2: Legal Representation - Investors who purchased Ultragenyx stock during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - Rosen Law Firm is reminding sellers of Endeavor Group Holdings, Inc. Class A common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements and omissions during a specified class period [1][5]. Group 1: Class Action Details - The class period for the lawsuit is defined as between January 15, 2025, and March 24, 2025, inclusive [1]. - Investors who sold Endeavor Class A common stock during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by March 18, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Allegations in the Lawsuit - The lawsuit seeks to recover damages for investors due to allegedly false and misleading statements made in the January 15, 2025 Information Statement filed with the SEC, which misrepresented the true value of Endeavor's shares and failed to disclose executive earnings and conflicts of interest [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Klarna Group plc about a class action lawsuit related to Klarna's September 2025 IPO, with a lead plaintiff deadline of February 20, 2026 [1][3]. Group 1: Class Action Details - Investors who purchased Klarna securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding Klarna's loss reserves, which were understated, leading to investor damages when the true information became public [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's actual efficacy [5][6]. - It is alleged that the Phase III Orbit and Cosmic studies were less likely to demonstrate the claimed benefits than management suggested, which misled investors [6]. Group 2: Investor Information - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A class action lawsuit has been filed against BlackRock TCP Capital Corp. for allegedly making materially false and misleading statements regarding its business operations and financial health during the Class Period from November 6, 2024, to January 23, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that BlackRock TCP failed to disclose that its investments were not being appropriately valued, which led to understated unrealized losses and an overstated net asset value (NAV) [5]. - Defendants allegedly made positive statements about BlackRock TCP's business that were materially misleading and lacked a reasonable basis [5]. - Investors are encouraged to join the class action to seek compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors [4]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently been in the top ranks since 2013 [4]. - Investors are advised to select qualified counsel with a proven success record, as many firms may not have comparable experience [4].

Core Viewpoint - Rosen Law Firm is reminding sellers of Endeavor Group Holdings, Inc. Class A common stock about a class action lawsuit related to alleged misleading statements and omissions during the Class Period from January 15, 2025, to March 24, 2025, with a lead plaintiff deadline of March 18, 2026 [1][5]. Group 1: Class Action Details - Investors who sold Endeavor Class A common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit aims to recover damages for investors misled by false statements and omissions in the January 15, 2025 Information Statement and related SEC filings [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and being ranked highly in the number of settlements achieved [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Company Overview - Inovio Pharmaceuticals is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating diseases, including those associated with human papillomavirus (HPV) [5]. Legal Allegations - The lawsuit claims that during the Class Period, Inovio made false and misleading statements, including: 1. Deficiencies in the manufacturing of Inovio's CELLECTRA device [5]. 2. Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. 3. Insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [5]. 4. Overstated regulatory and commercial prospects for INO-3107 [5]. - The lawsuit asserts that these misstatements led to investor damages when the true information became public [5]. Class Action Participation - Investors who purchased Inovio securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly [3][6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - The lawsuit alleges that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Firm Background - Rosen Law Firm specializes in securities class actions and has a strong track record, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - The founding partner of Rosen Law Firm was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4].

Group 1 - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Phoenix Education Partners, Inc. due to allegations of materially misleading business information [1] - Investors who purchased Phoenix Education securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A major data breach at the University of Phoenix affected nearly 3.5 million people, which may have implications for Phoenix Education's reputation and stock value [3] Group 2 - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [3] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [3]